Orbital Raises $270 Million in First Funding Round

RNA medicines developer Orbital Therapeutics has announced the successful closing of $270 million Series A financing. Orbital Therapeutics is focused on expanding the applicability of RNA-based medicines across a range of human diseases, including in the areas of next-generation vaccines, immunomodulation, and protein replacement.

“Few companies can possess the know-how, technology and biologic insights to deliver on the full breadth of opportunity that RNA medicines could provide for patients. Orbital was founded and has been built to be that special company,” said Kristina Burow, managing partner at lead investor ARCH Venture Partners, and co-founder and board director of Orbital. “We are pleased to partner with Orbital’s team of industry leaders and visionaries in drug development to help them achieve a bold mission of bringing forward the next generation of RNA-based medicines.”

According to its website, Orbital Therapeutics aims to enhance global health by unleashing the full potential of RNA-based medicines (excluding small interfering RNA) to treat human disease in ways that were not previously possible. The company is building a first-in-kind platform at the intersection of RNA technology, delivery methods, data science and automation to develop an expansive portfolio of medicines, initially focused in the areas of vaccines, immunomodulation, and protein replacement. (Source: Orbital Therapeutics Website, 26 April, 2023)